Nature Medicine Publishes Phase 3 Data on Pridopidine, Offering Hope in Early-Stage Huntington’s Disease Prilenia Therapeutics B.V., a clinical-stage biopharmaceutical company specializing in neurodegenerative diseases, together with its partner Ferrer, announced a significant milestone in the scientific and medical understanding…
Genentech Presents New Long-Term Data for Vabysmo in Wet AMD and PCV at Euretina Congress 2025 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), has announced compelling new data from two important clinical studies evaluating Vabysmo®…
Roche’s Vabysmo Reinforces Long-Term Benefits in Wet Age-Related Macular Degeneration and Shows Strong Gains in Polypoidal Choroidal Vasculopathy Paris, France – At the 25th annual Euretina Congress, one of the world’s most important scientific gatherings focused on retinal disease, Roche…
MEDIPAL Holdings and JCR Pharmaceuticals Expand Rare Disease Collaboration with Global Licensing and Japan Co-Development Agreement for JR-479, a Novel Investigational Therapy for GM2 Gangliosidosis In a significant advancement for patients and families affected by ultra-rare lysosomal storage disorders, MEDIPAL…
Enlaza Therapeutics and Vertex Pharmaceuticals Forge Multi-Billion-Dollar Collaboration to Advance Next-Generation Covalent Biologics in Autoimmune Diseases and Conditioning Therapies Enlaza Therapeutics (“Enlaza” or the “Company”), a pioneering biotechnology firm and the first company to build a dedicated covalent biologics platform,…
CapVest to Acquire Majority Stake in STADA from Bain Capital and Cinven CapVest Partners LLP (“CapVest”), a global investment firm with a reputation for building essential businesses across healthcare, consumer, and services sectors, has announced that it has signed a…
Daiichi Sankyo Advances Cardiovascular Care with Development of Oral Triple Combination Lipid-Lowering Tablets A New Chapter in Cholesterol Management Daiichi Sankyo Europe has unveiled an ambitious new initiative: the development of innovative oral triple combination tablets designed to help patients…
BeOne Medicines Announces Positive Topline Results from Phase 1/2 Study of Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company focused on advancing innovative treatments for hematologic malignancies,…
Enveric Biosciences Advances Neuropsychiatric Pipeline with Successful Completion of Dose Range Finding Studies for Lead Candidate EB-003 Enveric Biosciences, Inc. (NASDAQ: ENVB), a biotechnology company pioneering next-generation neuroplastogenic small-molecule therapeutics, announced that it has successfully completed 7-day Dose Range Finding…
SMSbiotech Advances to First-in-Human Phase 1 Clinical Trial for COPD with Innovative Stem Cell Therapy San Diego-based regenerative medicine company begins groundbreaking trial in Australia, aiming to restore lung function in millions of patients worldwide. SMSbiotech, a biotechnology company headquartered…
Strand Therapeutics Strengthens Leadership with Appointment of Dr. Jason J. Luke as Chief Medical Officer Strand Therapeutics, a biotechnology company pioneering programmable messenger RNA (mRNA) medicines, has announced the appointment of Jason J. Luke, MD, FACP, as its new Chief…
Savara’s Landmark IMPALA-2 Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis to Be Published in The New England Journal of Medicine Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company dedicated to advancing therapies for rare respiratory diseases,…